Burkitt lymphoma (BL) may be defined as an aggressive rare disorder that constitutes approximately 1% to 2% of all non-Hodgkin lymphomas. Burkitt lymphoma is known as one of the most aggressive forms of lymphoma, with a doubling time of approximately 24 hours. The term was coined after an Irish surgeon named Denis Burkitt, who first described the lymphoma in 1958, and was the first to successfully compile description of significant number of cases with the disorder. A range of intensive therapy regimen is available to choose from which depends upon local practice. The CODOX-M/IVAC is the most commonly administered regimen, first introduced as pediatric regimen in 1980 by Magrath et.al. Various regimen for Burkitt lymphoma (BL) are R-CODOX-M/IVAC regimen, BFM/GMALL/NHL regimen, Hyper-CVAD regimen, CALGB and LMB regimen, DA-EPOCH-R regimen, and other high-intensive regimens. Burkitt lymphoma is represented by three clinical sub-types: endemic Burkitt lymphoma (eBL), immunodeficiency-associated Burkitt lymphoma (iBL), and sporadic (sBL). These clinical sub-types share similar morphological and immunophenotypic features, while conform largely with respect to genetic makeup, and differ in exhibiting few clinical features as well as incidence pattern. Sporadic Burkitt lymphoma (sBL) is a rare disorder generally affecting all age groups. It accounts for approximately 1% of adult lymphomas and reported in areas lacking endemic malaria. Endemic Burkitt lymphoma (eBL) is predominantly a pediatric disease or disorder, accounting for about 30% to 50% of pediatric cancer in regions with holoendemic malaria. Endemic Burkitt lymphoma (eBL) clinically differs by affecting facial bones especially the jaw. Immunodeficiency-associated Burkitt lymphoma (iBL) accounts for 10% to 40% of all HIV (Human Immunodeficiency Virus) associated lymphomas and was the first to be recognized in HIV setting.
The CODOX-M/IVAC regimen includes cytarabine, cyclophosphamide, doxorubicin, etoposide, high-dose cytarabine, IT methotrexate, leucovorin, vincristine/ifosfamide. BFM/GMALL/NHL regimen generally consists of pre-phase treatment with prednisone and cyclophosphamide, which is then commenced by alternating chemotherapy with six cycles including doxorubicin, dexamethasone, ifosfamide, high-dose methotrexate, teniposide, cytarabine, and vincristine. It also includes triple IT therapy with cytarabine, dexamethasone, and methotrexate. Hyper-CVAD regimen which was initially developed for acute lymphoblastic leukemia includes four cycles of hyperfractionated cyclophosphamide, dexamethasone, vincristine, and doxorubicin. CALGB and LMB regimens utilize prednisone and cyclophosphamide as a pre-phase cycle, followed by alternating chemotherapy cycles depending upon the risk. DA-EPOCH-R regimen consists of different approach with low concentration chemotherapy agents being exposed for long period of time as compared to that of other high-intensive regimen, comprising infusional EPOCH (cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone). This regimen is specifically used in order to provide continuous exposure of cytotoxic agents to tumor cells and to bring about decrease in toxicity. Many variations of short-cycle, high intensive regimens are being developed and used in addition to these regimens.
The global Burkitt lymphoma (BL) therapeutics market can be segmented based on clinical type, drug therapy regimen, distribution channel, and region. In terms of clinical type, the market can be classified into endemic BL (eBL), immunodeficiency-associated BL (idBL), and sporadic variant (sBL). Based on drug therapy regimen, the global Burkitt lymphoma (BL) therapeutics market can be categorized into R-CODOX-M/IVAC regimen, BFM/GMALL/NHL regimen, Hyper-CVAD regimen, CALGB and LMB regimen, DA-EPOCH-R, and other high-intensive regimens. In terms of distribution channel, the market can be divided into drug stores, hospital pharmacy, online pharmacy, retail pharmacy, and others.
In terms of region, the global Burkitt lymphoma (BL) therapeutics market can be segmented into Asia Pacific, Europe, Middle East & Africa, North America, and Latin America.
Key players in the global Burkitt lymphoma (BL) therapeutics market are Bedford Laboratories, Sun Pharma, Seattle Genetics, Inc., Sanofi, Mayo Clinic, Pfizer, Inc., Merck KGaA, and Cellerant Therapeutics, Inc., among others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.